Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 8/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 8/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6444533 | 0.92 | SMN1; SMN2 (0.39) | CTDSP1CYP1A2SMN1; SMN2GRIN1GRIN2B | |
| SCHEMBL6200741 | 0.86 | ALDH1A1 (0.39) | CYP1A2L3MBTL1MEN1KMT2AALDH1A1 | |
| SCHEMBL6806341 | 0.83 | CTDSP1 (0.38) | CTDSP1CYP1A2GRIN1GRIN2BBRD4 | |
| SCHEMBL6445203 | 0.83 | CSF1R (0.35) | SMN1; SMN2MAPTPLA2G2AKMT2AALDH1A1 | |
| SCHEMBL6443373 | 0.81 | ALDH1A1 (0.44) | CYP1A2SMN1; SMN2MAPTPLA2G2AMEN1 | |
| SCHEMBL6444199 | 0.80 | SMN1; SMN2 (0.43) | CTDSP1CYP1A2SMN1; SMN2GRIN1GRIN2B | |
| SCHEMBL6443509 | 0.80 | CSF1R (0.37) | CTDSP1SMN1; SMN2GRIN1GRIN2BL3MBTL1 | |
| Bicarbonate SCHEMBL7386270 | 0.78 | ALDH1A1 (0.42) | CYP1A2SMN1; SMN2MAPTPLA2G2AMEN1 | |
| Bicarbonate SCHEMBL7386267 | 0.78 | ALDH1A1 (0.42) | CYP1A2SMN1; SMN2MAPTPLA2G2AMEN1 | |
| Bicarbonate SCHEMBL7386268 | 0.78 | ALDH1A1 (0.42) | CYP1A2SMN1; SMN2MAPTPLA2G2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1371647-B1 | Pyridine-3-carboxylic acid derivatives and their use as intermediates | PFIZER (US) | 2005-07-13 | — | — | EP | disclosed |
| US-6770645-B2 | SEXUAL DISORDERS THERAPY; ANTIALLERGENS; RESPIRATORY SYSTEM DISORDERS | PFIZER INC. | 2004-08-03 | — | — | US | disclosed |
| EP-1371647-A2 | Pyridine-3-carboxylic acid derivatives and their use as intermediates | PFIZER INC. (US) | 2003-12-17 | — | — | EP | disclosed |
| EP-1073658-B1 | PYRAZOLOPYRIMIDINONE CGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER (US) | 2003-08-13 | — | — | EP | disclosed |
| US-20030064990-A1 | Pharmaceutically active compounds | PFIZER INC. | 2003-04-03 | — | — | US | disclosed |
| US-6458951-B2 | FOR TREATMENT OF MALE ERECTILE DYSFUNCTION, FEMALE SEXUAL DYSFUNCTION | PFIZER INC | 2002-10-01 | — | — | US | disclosed |
| US-20010039271-A1 | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | BUNNAGE MARK EDWARD (GB) | 2001-11-08 | — | — | US | disclosed |
| US-6251904-B1 | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | PFIZER INC. | 2001-06-26 | — | — | US | disclosed |
| EP-1073658-A1 | PYRAZOLOPYRIMIDINONE CGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER INC. (US) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999054333-A1 | PYRAZOLOPYRIMIDINONE CGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER INC. (US) | 1999-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039271-A1 | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | PDE5A, PDE3A, PDE3B | CTDSP1 2619/4885CYP1A2 122/4885SMN1; SMN2 1854/4885 |
| US-20030064990-A1 | Pharmaceutically active compounds | PDE5A, PDE3A, PDE2A | CTDSP1 1555/4885CYP1A2 429/4885SMN1; SMN2 2159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.